| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Laboratories of Pharmacology [T-C. C., T. J. B., F. S. P.], Applied Therapy [J. H. B.], Experimental Antitumor Testing [F. A. S.], and Organic Chemistry [T-L. S., K. A. W., J. J. F.], Memorial Sloan-Kettering Cancer Center, New York, New York 10021
2'-Fluoro-5-methyl-1-ß-D-arabinofuranosyluracil (FMAU), like 2'-fluoro-5-iodo-1-ß-D-arabinofuranosylcytosine (FIAC), has potent antiviral activity, but unlike FIAC, it also has antileukemic effects. The two agents and 1-ß-D-arabinofuranosylcytosine (ara-C) are compared herein. Concentrations inhibiting thymidine (dThd) incorporation into DNA by 50% are for FMAU, FIAC, and ara-C, respectively, in L1210/0, 32, 353, and 0.2 µM and in L1210/ara-C, 17, >10,000, and 3,900 µM. Other FMAU analogs, 2'-fluoro-5-iodo-1-ß-D-arabinofuranosyluracil and 2'-fluoro-5-ethyl-1-ß-D-arabinofuranosyluracil, inhibit dThd incorporation equally in ara-C-sensitive and -resistant cells; however, their potencies are weaker than that of FMAU. Similar results are obtained when [3H]deoxyadenosine is used as a precursor of incorporation. In L1210/0 cells, incorporation of [2-14C]FMAU radioactivity into DNA is competitively inhibited by dThd and deoxycytidine (dCyd), whereas the incorporation of [2-14C]FIAC radioactivity is competitively inhibited by dCyd but not appreciably by dThd. In L1210/ara-C cells, incorporation of [2-14C]FMAU is competitively inhibited by dThd but not by dCyd. In L1210/0 cells, FMAU has little inhibitory effect on the tritium release from [5-3H]deoxyuridine but markedly inhibits the incorporation of [2-14C]deoxyuridine into DNA. FIAC, by contrast, predominately inhibits the release of tritium from [5-3H]deoxyuridine but has little effect on subsequent incorporation into DNA. These results suggest that (a) FIAC, but not FMAU, is cross-resistant to ara-C; (b) FMAU is particularly effective against L1210/ara-C cells; (c) FIAC behaves metabolically like dCyd, and FMAU like dThd and dCyd; (d) dCyd and dThd may be used as chemotherapeutic modulators; and (e) FIAC predominately inhibits dThd kinase and/or thymidine monophosphate synthetase, whereas FMAU predominately inhibits DNA polymerase and/or nucleotide kinases. Similar conclusions were obtained when P815/0 and P815/ara-C cells were used. The relative potencies of FIAC and FMAU in inhbiting dThd incorporation into DNA in leukemic sublines correlate with cytotoxicity in vitro and chemotherapeutic effects in vivo.
1 This work was supported by National Cancer Institute Grants CA 27569, CA 18856, CA 08748, CA 18601, and CA 09207 and by the Elsa U. Pardee Foundation.
2 To whom requests for reprints should be addressed.
Received 1/28/82. Accepted 6/29/82.
This article has been cited by other articles:
![]() |
T.-C. Chou Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies Pharmacol. Rev., September 1, 2006; 58(3): 621 - 681. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-H. Liu, K. L. Grove, and Y.-C. Cheng Unique Metabolism of a Novel Antiviral L-Nucleoside Analog, 2'-Fluoro-5-Methyl-beta -L-Arabinofuranosyluracil: a Substrate for Both Thymidine Kinase and Deoxycytidine Kinase Antimicrob. Agents Chemother., April 1, 1998; 42(4): 833 - 839. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |